Alyftrek is approved as a new treatment for cystic fibrosis, while the FDA expanded the label for Trikafta to include additional genetic mutations.
The drug combo is the first dual checkpoint inhibitor therapy approved in Europe for first-line metastatic MSI-H or dMMR colorectal cancer.
NEW YORK – 2024 was a banner year of "firsts" in the gene therapy space, as the US Food and Drug Administration greenlit ...
NEW YORK – AstraZeneca on Monday said the European Commission approved its tyrosine kinase inhibitor Tagrisso (osimertinib) as a treatment for patients with advanced, unresectable non-small cell lung ...
Scipher will contribute data derived from its PrismRA blood test to the Atropos Evidence Network, which underpins software tools, including an AI chatbot.
The firm plans to launch trials to study the agent in biomarker-defined cancer types, including breast and lung cancers.
The drugmaker said that the agents vibostolimab and favezelimab failed to show benefit across numerous trials.
The firms have teamed up on a Phase I trial to evaluate the off-the-shelf cell therapy SN301A in patients with advanced GPC3-expressing liver cancers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback